Atypical haemolytic uraemic syndrome and pregnancy: Outcome with ongoing eculizumab

Nephrology Dialysis Transplantation

Volumn 31, Issue 12, 2016, Pages 2122-2130

  Servais, Aude ^a,b   Devillard, Nadège ^c   Frémeaux Bacchi, Véronique ^d,e   Hummel, Aurélie ^a,b   Salomon, Laurent ^a,b   Contin Bordes, Cécile ^f   Gomer, Hélène ^g   Legendre, Christophe ^a,b   Delmas, Yahsou ^g  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY HOSPITAL OF BESANÇON   (France)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f CNRS Bordeaux Segalen University   (France)

^g BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Atypical haemolytic uraemic syndrome; Eculizumab; HELLP syndrome; Pre eclampsia; Pregnancy

Indexed keywords

CREATININE; ECULIZUMAB; COMPLEMENT INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONCEPTION; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG DOSE INCREASE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FETUS DEATH; GESTATION PERIOD; GROWTH RETARDATION; HELLP SYNDROME; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTRANSAMINASEMIA; PLATELET COUNT; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREGNANCY RATE; PRIORITY JOURNAL; TREATMENT OUTCOME; ATYPICAL HEMOLYTIC UREMIC SYNDROME; BLOOD; PREGNANCY COMPLICATIONS;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT INACTIVATING AGENTS; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; TREATMENT OUTCOME;

EID: 85026919072     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfw314     Document Type: Article

References (33)

1. Zuber J, Fakhouri F, Roumenina LT et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012; 8: 643-657.
2. Legendre CM, Licht C, Muus P et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368: 2169-2181.
3. Kelly RJ, Hochsmann B, Szer J et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2015; 373: 1032-1039.
4. Kelly R, Arnold L, Richards S et al. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol 2010; 149: 446-450.
5. Danilov AV, Brodsky RA, Craigo S et al. Managing a pregnant patient with paroxysmal nocturnal hemoglobinuria in the era of eculizumab. Leuk Res 2010; 34: 566-571.
6. Marasca R, Coluccio V, Santachiara R et al. Pregnancy in PNH: another eculizumab baby. Br J Haematol 2010; 150: 707-708.
7. ArdissinoG,WallyOssolaM,BafferoGMetal.Eculizumabforatypicalhemo-lytic uremic syndrome in pregnancy. Obstet Gynecol 2013; 122(2 Pt 2): 487-489.
8. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
9. Dragon-Durey MA, Fremeaux-Bacchi V, Loirat C et al. Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol 2004; 15: 787-795.
10. Roumenina LT, Loirat C, Dragon-Durey MA et al. Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods 2011; 365: 8-26.
11. Fakhouri F, Roumenina L, Provot F et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 2010; 21: 859-867.
12. Caprioli J, Noris M, Brioschi S et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006; 108: 1267-1279.
13. Hillmen P, Hall C, Marsh JC et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004; 350: 552-559.
14. Hillmen P, Young NS, Schubert J et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355: 1233-1243.
15. Brodsky RA, Young NS, Antonioli E et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008; 111: 1840-1847.
16. Hallstensen RF, Bergseth G, Foss S et al. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Im-munobiology 2015; 220: 452-459.
17. Rother RP, Rollins SA, Mojcik CF et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nate Biotechnol 2007; 25: 1256-1264.
18. Simister NE. Placental transport of immunoglobulin G. Vaccine 2003; 21: 3365-3369.
19. Gatault P, Brachet G, Ternant D et al. Therapeutic drug monitoring of eculizumab: rationale for an individualized dosing schedule. MAbs 2015; 7: 1205-1211.
20. Peffault de Latour R, Fremeaux-Bacchi V, Porcher R et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood 2015; 125: 775-783.
21. Delmas Y, Bordes C, Loirat C et al. Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice. Clin Kidney J 2013; 6: 243-244.
22. Girardi G, Bulla R, Salmon JE et al. The complement system in the pathophysiology of pregnancy. Mol Immunol 2006; 43: 68-77.
23. Johnson U, Gustavii B. Complement components in normal pregnancy. Acta Pathol Microbiol Immunol Scand C 1987; 95: 97-99.
24. Lynch AM, Murphy JR, Byers T et al. Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am J Obstet Gynecol 2008; 198: 385 e1-9.
25. Fakhouri F, Jablonski M, Lepercq J et al. Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. Blood 2008; 112: 4542-4545.
26. Haeger M, Unander M, Norder-Hansson B et al. Complement, neutrophil, and macrophage activation in women with severe preeclampsia and the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 1992; 79: 19-26.
27. Derzsy Z, Prohaszka Z, Rigo J, Jr et al. Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol 2010; 47: 1500-1506.
28. de Messias-Reason IJ, Aleixo V, de Freitas H et al. Complement activation in Brazilian patients with preeclampsia. J Investig Allergol Clin Immunol 2000; 10: 209-214.
29. Girardi G, Yarilin D, Thurman JM et al. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 2006; 203: 2165-2175.
30. Rampersad R, Barton A, Sadovsky Y et al. The C5b-9 membrane attack complex of complement activation localizes to villous trophoblast injury in vivo and modulates human trophoblast function in vitro. Placenta 2008; 29: 855-861.
31. Burwick RM, Feinberg BB. Eculizumab for the treatment of preeclampsia/ HELLP syndrome. Placenta 2013; 34: 201-203.
32. Piccoli GB, Cabiddu G, Attini R et al. Risk of adverse pregnancy outcomes in women with CKD. J Am Soc Nephrol 2015; 26: 2011-2022.
33. Imbasciati E, Gregorini G, Cabiddu G et al. Pregnancy in CKD stages 3 to 5: fetal and maternal outcomes. Am J Kidney Dis 2007; 49: 753-762.